[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100592418":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":11,"centralContacts":23,"locations":33,"responsibleParty":48,"collaborators":11,"id":50,"slug":51,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":11,"eligibilityCriteria":56,"healthyVolunteers":57,"sex":58,"minAge":59,"maxAge":11,"enrollmentInfo":60,"targetDuration":11,"studyType":63,"phases":64,"briefSummary":66,"conditions":67,"keywords":11,"overallStatus":69,"whyStopped":11,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":79},{"fullName":5,"class":6},"Dong-A ST Co., Ltd.","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Sequence A","EXPERIMENTAL",null,[13],"Drug: DA-5222",{"label":15,"type":10,"description":11,"interventionNames":16},"Sequence B",[13],[18],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":11},"DRUG","DA-5222","single dose administration (DA-5222 one tablet once a day)",[9,15],[24,29],{"name":25,"role":26,"phone":27,"phoneExt":11,"email":28},"Jihyun Sung","CONTACT","+82-02-920-8369","jhsung@donga.co.kr",{"name":30,"role":26,"phone":31,"phoneExt":11,"email":32},"Heechan Jung","+82-02-920-8322","hcjung@donga.co.kr",[34],{"facility":35,"status":11,"city":36,"state":37,"zip":11,"country":37,"countryCode":11,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"Bumin Hospital","Seoul","South Korea",{"type":39,"coordinates":40},"Point",[41,42],126.9784,37.566,{"lat":42,"lon":41},[45],{"name":46,"role":26,"phone":11,"phoneExt":11,"email":47},"Taegon Hong, Ph.D","tghong@bumin.co.kr",{"type":49,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100592418","phase-1-to-evaluate-effect-of-food-of-da-5222-in-healthy-adult-subjects-100592418",false,"NCT06993168","To Evaluate Effect of Food of DA-5222 in Healthy Adult Subjects","An Open-label, Randomized, Single-dose, 2-sequence, 2-period, Crossover Phase 1 Study to Evaluate the Effect of Food on the Pharmacokinetic Characteristics of DA-5222 in Healthy Adult Subjects","Inclusion Criteria:\n\n* Healthy volunteers\n* BMI between 18 and 30 kg\u002Fm2\n* Body weight: Male≥50kg, Female≥45kg\n* Subjects who have signed an informed consent themselves after receiving detailed explanation about clinical study\n\nExclusion Criteria:\n\n* Subjects with clinically significant medical history\n* Subjects with history of drug abuse or addicted\n* Subjects with allergy or drug hypersensitivity",true,"ALL","19 Years",{"count":61,"type":62},32,"ESTIMATED","INTERVENTIONAL",[65],"PHASE1","This study is to evaluate the effect of food on pharmacokinetics of DA-5222 in healthy adult subjects",[68],"Healthy","NOT_YET_RECRUITING","2025-05-19",{"date":72,"type":73},"2025-05-28","ACTUAL",{"date":75,"type":62},"2025-05-21",{"date":77,"type":62},"2025-07",{"name":5,"class":6},1]